Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Build A Bear Workshop Inc (BBW) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Build A Bear Workshop IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Build A Bear Workshop Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.42 (market cap $29.60B), while Build A Bear Workshop Inc trades at $37.1 (market cap $461.88M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 64.1× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYBBW
Market Cap
$29.60B$461.88M
Sector
HealthConsumer Cyclical
52-Week High
$491.22$75.85
52-Week Low
$205.48$29.84
Enterprise Value
$27.56B$561.32M
Dividend Yield
2.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

Build A Bear Workshop Inc

Build-A-Bear Workshop (BBW) trades at $36.09, down 3.14% today, but maintains strong fundamentals with a P/E of 8.63 and robust profitability metrics including 35.87% ROE. The stock shows technical bullish signals with moving averages supporting upward momentum, though RSI levels suggest potential near-term overbought conditions. Recent earnings beats and strategic product launches position the company for continued growth despite current price weakness.

BBW presents compelling value with analyst consensus price target of $62.50 representing 73% upside potential. The debt-free balance sheet, consistent dividend payments, and international expansion strategy support long-term growth, though near-term consumer spending pressures and competitive retail environment pose execution risks for investors.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Build A Bear Workshop Inc

Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.

Read more on BBW